ライフサイエンスコーパス: retinal vein

1 chemic by laser occlusion of the main branch retinal veins.

2 etinal hemorrhages, and dilated and tortuous retinal veins.

3 Central retinal vein and central retinal arterial equivalents we

4 arterial occlusion (5/16), combined central retinal vein and cilioretinal artery occlusion (4/16), a

5 erve head capillaries drain into the central retinal vein and veins of the optic nerve sheath.

6 th, elevation of the pressure in the central retinal vein, and impaired perfusion of the neurons as t

7 was used to measure P(O2) separately in the retinal veins, arteries, and capillaries and in the chor

8 the central retinal vein (CRVO) or a branch retinal vein (BRVO).

9 and hemodynamic changes in a major temporal retinal vein by laser Doppler, before and after plasmaph

10 SPCA), central retinal artery (CRA), central retinal vein (CRV), peripapillary choroid and sclera, an

11 e vision loss due to blockage of the central retinal vein (CRVO) or a branch retinal vein (BRVO).

12 h smaller central retinal artery and central retinal vein diameters.

13 In the hypoxic study, cerebral and retinal vein engorgement were correlated, and rose as th

14 al retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and arteriole-to-venule

15 al retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and arteriole-to-venule

16 entral retinal artery equivalent and central retinal vein equivalent from baseline to 1 week (from 17

17 Conversely, mean central retinal vein equivalent was 195.5 +/- 9.91 MU in healthy

18 Central retinal vein equivalents ranged from 228.93 +/- 21.26 mi

19 Both the dilation of the conjunctiva and retinal veins improved.

20 were measured in the major superior temporal retinal vein in each subject by using a laser Doppler in

21 d by a robot micromanipulator, while a major retinal vein near the optic disc was occluded by argon l

22 hile 7 eyes demonstrated obvious findings of retinal vein obstruction (5 with central and 2 with hemi

23 fit, particularly for those eyes with branch retinal vein obstruction and poorer vision.

24 ondary to outflow obstruction from a central retinal vein obstruction appears to be the most common c

25 bstruction (typically central or hemicentral retinal vein obstruction) using en face optical coherenc

26 n shown to be of benefit in eyes with branch retinal vein obstruction.

27 pathy; (3) laser photocoagulation for branch retinal vein obstruction; (4) diabetic vitrectomy; (5) t

28 rtery occlusion (4/16), and isolated central retinal vein occlusion (4/16).

29 betic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO).

30 tral retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) causes hypoperfusion, high

31 ral retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular ede

32 olume distensibility in patients with branch retinal vein occlusion (BRVO) in comparison with normal

33 natural history of visual outcome in branch retinal vein occlusion (BRVO) is fundamental to its mana

34 Branch retinal vein occlusion (BRVO) is second only to diabetic

35 optic nerve head (ONH) parameters and branch retinal vein occlusion (BRVO) using spectral domain opti

36 venous crossings are risk factors for branch retinal vein occlusion (BRVO), an eye disease in which c

37 ent due to macular edema secondary to branch retinal vein occlusion (BRVO).

38 ection for macular edema secondary to branch retinal vein occlusion (BRVO).

39 ) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

40 ative diabetic retinopathy (PDR), and branch retinal vein occlusion (BRVO).

41 nt of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

42 aphy angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein oc

43 o review the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of n

44 To determine the outcome of central retinal vein occlusion (CRVO) in pre-existing glaucoma a

45 Central retinal vein occlusion (CRVO) or branch retinal vein occ

46 ents with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlus

47 ble to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlus

48 fty-five patients with a nonischemic central retinal vein occlusion (CRVO) who were randomized to rec

49 To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recen

50 ers a distinctive retinopathy with a central retinal vein occlusion (CRVO)-like appearance.

51 perfused macular edema in eyes with central retinal vein occlusion (CRVO).

52 nch retinal (BRVO), hemi-retinal and central retinal vein occlusion (CRVO).

53 CG) in eyes with the recent onset of central retinal vein occlusion (CRVO).

54 etic macular edema (DME), central and branch retinal vein occlusion (CRVO/BRVO), central serous chori

55 eneration (HR = 1.29; 95% CI: 1.08-1.54) and retinal vein occlusion (HR = 3.94; 95% CI: 3.11-4.99).

56 r managing complications of ischemic central retinal vein occlusion (iCRVO).

57 h retinal arterial occlusion (n = 3), branch retinal vein occlusion (n = 1), vitamin A deficiency (n

58 E (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7),

59 .07), uveitis (RR, 2.88; 95% CI, 1.50-5.51), retinal vein occlusion (RR, 4.47; 95% CI, 2.56-5.92), or

60 R), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused through a hypoxi

61 Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due t

62 Results of ocular biometric measurements in retinal vein occlusion (RVO) eyes are still inconclusive

63 the prevalence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of

64 the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naive patients

65 PURPOSE OF REVIEW: Retinal vein occlusion (RVO) is a sight-threatening reti

66 ion (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson c

67 lopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age relate

68 ents with diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential

69 decreased visual acuity (VA) associated with retinal vein occlusion (RVO).

70 genotype, folate and vitamin B12 status, and retinal vein occlusion (RVO).

71 (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO).

72 aturity (ROP), diabetic retinopathy (DR) and retinal vein occlusion (RVO).

73 r treatment of macular edema associated with retinal vein occlusion (RVO).

74 ), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeis

75 The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravi

76 the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE)-CRVO trial, CRUISE Study,

77 ercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received ei

78 nsive retinopathy 0.88%, macular scar 0.37%, retinal vein occlusion 0.50%, macular hole 0.20%, retini

79 s in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with co

80 s in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).

81 ) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline

82 n occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]).

83 at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch

84 derived anatomic measurements between branch retinal vein occlusion and central retinal vein occlusio

85 e main are age-related macular degeneration, retinal vein occlusion and diabetic macular edema.

86 In patients with central retinal vein occlusion and initially low visual acuity,

87 thickness in patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in c

88 sive patient, who developed bilateral branch retinal vein occlusion at 6T, the therapy was discontinu

89 pain score) and similar to patients in other retinal vein occlusion clinical trials.

90 uently developed retinal artery occlusion or retinal vein occlusion compared with patients undergoing

91 retinopathy, glaucoma, and branch or central retinal vein occlusion diagnosis.

92 ve (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26).

93 and the absence of such a difference in the retinal vein occlusion group could be explained by edema

94 = 0.024); however, the same analysis in the retinal vein occlusion group revealed no significant dif

95 en branch retinal vein occlusion and central retinal vein occlusion groups (all P >/= 0.058); therefo

96 Patients with retinal vein occlusion had higher risks of hemorrhagic s

97 to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than

98 ged 18 years with macular edema secondary to retinal vein occlusion in the branch vein occlusion (BRA

99 Retinal vein occlusion is a common retinal vascular diso

100 Retinal ischemic damage associated with retinal vein occlusion is exacerbated by fluid extravasa

101 ve of best-corrected visual acuity (BCVA) in retinal vein occlusion macular edema (RVO-ME).

102 pressure in the cat after acute experimental retinal vein occlusion may define the role of intravascu

103 Cystoid macular edema in retinal vein occlusion occurred in relation to altered i

104 retinal vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 i

105 The Collaborative Central Retinal Vein Occlusion Study has recently reported infor

106 2 patients, one each with Eales' disease and retinal vein occlusion the procedure was unsuccessful, n

107 reference populations and patients in other retinal vein occlusion trials.

108 ORE2) and to compare with cohorts from other retinal vein occlusion trials.

109 Central retinal vein occlusion was associated with an overall in

110 Retinal vein occlusion was observed in some Cbs(+/-) mou

111 tinal artery occlusion and 463 patients with retinal vein occlusion were enrolled and matched for age

112 two patients with macular edema secondary to retinal vein occlusion were enrolled in the study.

113 Treatment of macular edema secondary to retinal vein occlusion with ranibizumab has been shown t

114 rysm with subretinal hemorrhage (1), central retinal vein occlusion with vitreous hemorrhage (1), and

115 ction (5 with central and 2 with hemicentral retinal vein occlusion), 4 eyes were unremarkable at pre

116 tinal artery occlusion and 463 patients with retinal vein occlusion, 66 (58.4%) and 245 (52.9%) were

117 contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter tr

118 , diabetic macular edema, central and branch retinal vein occlusion, and miscellaneous causes.

119 , in models of retinal degeneration, central retinal vein occlusion, and oxygen-induced retinopathy.

120 such as proliferative diabetic retinopathy, retinal vein occlusion, and retinal detachment, than in

121 omplication of retinal ischemia in diabetes, retinal vein occlusion, and retinopathy of prematurity.

122 nal diseases including diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity.

123 In retinal vein occlusion, both ranibizumab and Ozurdex hav

124 ab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determ

125 ration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal neovascularization (CN

126 ular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) ha

127 the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, a

128 cation of diabetes mellitus, prematurity, or retinal vein occlusion, is a major cause of blindness wo

129 In eyes with retinal vein occlusion, longer ME duration at the time o

130 g, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular hole, epiretinal membran

131 , diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, whi

132 , leakage such as macular edema secondary to retinal vein occlusion, or a combination of proliferatio

133 This suggests that prompt treatment for retinal vein occlusion, particularly BRVO, may be associ

134 agent ranibizumab in diabetic macular edema, retinal vein occlusion, pseudophakic macular edema, and

135 diverse conditions as diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exud

136 condary to AMD or Macular Edema Secondary to Retinal Vein Occlusion, Safety Assessment of Intravitrea

137 conditions, including diabetic retinopathy, retinal vein occlusion, sickle cell retinopathy, uveitis

138 te to progression of retinal nonperfusion in retinal vein occlusion, the same is true in patients wit

139 mic diseases including diabetic retinopathy, retinal vein occlusion, uveitis, and HIV-related retinit

140 In retinal vein occlusion, venous pressures in a segmental

141 e patients, 3 with branch and 9 with central retinal vein occlusion, were imaged in 27 sessions with

142 tic neuropathy in contrast to what occurs in retinal vein occlusion, where edema affects all retinal

143 eyes with macular edema secondary to central retinal vein occlusion, which were treated with a dexame

144 oliferative diabetic retinopathy and central retinal vein occlusion.

145 s can be an innovative tool in management of retinal vein occlusion.

146 eneration (AMD), diabetic macular edema, and retinal vein occlusion.

147 cular degeneration, diabetic maculopathy, or retinal vein occlusion.

148 eovascularization in the pig model of branch retinal vein occlusion.

149 he treatment of macular edema due to central retinal vein occlusion.

150 cluded from the therapy approval studies for retinal vein occlusion.

151 and treatment of recurrent macular edema in retinal vein occlusion.

152 quantify macular edema in central and branch retinal vein occlusion.

153 improving visual acuity in participants with retinal vein occlusion.

154 efield angiogram images of eyes with central retinal vein occlusion.

155 edema secondary to either central or branch retinal vein occlusion.

156 egeneration or macular edema attributable to retinal vein occlusion.

157 ration: 34.2 %; diabetic retinopathy: 4.2 %; retinal vein occlusion: 3.8 %).

158 patients with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein

159 pth (VCD) and both central (CRVO) and branch retinal vein occlusions (BRVO) using optical low coheren

160 sc were made for 13 patients with DE (7 with retinal vein occlusions and 6 with inflammatory optic ne

161 ckings (AVNs) in the retina are the cause of retinal vein occlusions and are also surrogates of cereb

162 ortant implications for the understanding of retinal vein occlusions and of cerebrovascular aging.

163 discussing the prognosis and risk factors of retinal vein occlusions and the treatment options.

164 caused by inflammatory optic neuropathies or retinal vein occlusions on optical coherence tomography

165 CE PATTERN(R) GUIDELINES: New evidence-based Retinal Vein Occlusions Preferred Practice Pattern(R) (P

166 RETINAL VEIN OCCLUSIONS PREFERRED PRACTICE PATTERN(R) GU

167 In 20 eyes of 10 pigs, branch retinal vein occlusions were created in a standardized m

168 Retinal vein occlusions were further divided into branch

169 erative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses.

170 ge-related macular degeneration, and central retinal vein occlusions.

171 Direct measurement of the retinal vein pressure in the cat after acute experimenta

172 After occlusion, retinal vein pressures were measured on both sides of th

173 Upstream of the occlusion site, the retinal vein pressures were not greatly elevated, althou

174 horoidal sinus communicates with the central retinal vein, the choriocapillaris, and with large veins

175 ue plasminogen activator, 3) cannulating the retinal vein transvitreally, or 4) transecting the poste

176 inogen activator (rt-PA), 3) cannulating the retinal vein transvitreally, or 4) transecting the poste

177 ere used to create a vascular overlay of the retinal veins vs the retinal arteries to map the distrib

178 Flow in retinal veins was calculated from the OCT velocity profi

179 was induced in cat retina by coagulation of retinal veins with diathermy.